nodes	percent_of_prediction	percent_of_DWPC	metapath
Irbesartan—CYP3A4—prostate cancer	0.115	1	CbGaD
Irbesartan—CYP2C8—Nilutamide—prostate cancer	0.0361	0.076	CbGbCtD
Irbesartan—CYP2C8—Abiraterone—prostate cancer	0.0299	0.063	CbGbCtD
Irbesartan—CYP3A4—Estradiol valerate/Dienogest—prostate cancer	0.0279	0.0587	CbGbCtD
Irbesartan—CYP2C9—Nilutamide—prostate cancer	0.0252	0.053	CbGbCtD
Irbesartan—CYP2C9—Bicalutamide—prostate cancer	0.0252	0.053	CbGbCtD
Irbesartan—CYP1A2—Flutamide—prostate cancer	0.0232	0.0488	CbGbCtD
Irbesartan—CYP2D6—Bicalutamide—prostate cancer	0.023	0.0485	CbGbCtD
Irbesartan—CYP2C8—Cabazitaxel—prostate cancer	0.0221	0.0466	CbGbCtD
Irbesartan—CYP2C8—Ethinyl Estradiol—prostate cancer	0.0193	0.0406	CbGbCtD
Irbesartan—CYP2D6—Abiraterone—prostate cancer	0.0191	0.0402	CbGbCtD
Irbesartan—CYP1A2—Estrone—prostate cancer	0.0167	0.0353	CbGbCtD
Irbesartan—CYP2C9—Estrone—prostate cancer	0.0151	0.0318	CbGbCtD
Irbesartan—CYP3A4—Bicalutamide—prostate cancer	0.0146	0.0308	CbGbCtD
Irbesartan—PTGS1—Etoposide—prostate cancer	0.0141	0.0296	CbGbCtD
Irbesartan—CYP3A4—Estramustine—prostate cancer	0.0136	0.0287	CbGbCtD
Irbesartan—CYP2C8—Estradiol—prostate cancer	0.0124	0.0262	CbGbCtD
Irbesartan—CYP3A4—Flutamide—prostate cancer	0.0121	0.0256	CbGbCtD
Irbesartan—CYP3A4—Abiraterone—prostate cancer	0.0121	0.0256	CbGbCtD
Irbesartan—CYP2C9—Capecitabine—prostate cancer	0.0114	0.0241	CbGbCtD
Irbesartan—CYP1A2—Conjugated Estrogens—prostate cancer	0.011	0.0231	CbGbCtD
Irbesartan—CYP1A2—Estradiol—prostate cancer	0.00961	0.0203	CbGbCtD
Irbesartan—CYP3A4—Cabazitaxel—prostate cancer	0.00897	0.0189	CbGbCtD
Irbesartan—CYP3A4—Estrone—prostate cancer	0.00877	0.0185	CbGbCtD
Irbesartan—CYP2C9—Estradiol—prostate cancer	0.00866	0.0183	CbGbCtD
Irbesartan—CYP2C8—Etoposide—prostate cancer	0.00811	0.0171	CbGbCtD
Irbesartan—CYP3A4—Ethinyl Estradiol—prostate cancer	0.00782	0.0165	CbGbCtD
Irbesartan—CYP1A2—Etoposide—prostate cancer	0.00628	0.0132	CbGbCtD
Irbesartan—CYP3A4—Conjugated Estrogens—prostate cancer	0.00574	0.0121	CbGbCtD
Irbesartan—CYP3A4—Mitoxantrone—prostate cancer	0.00522	0.011	CbGbCtD
Irbesartan—CYP3A4—Estradiol—prostate cancer	0.00504	0.0106	CbGbCtD
Irbesartan—CYP3A4—Prednisone—prostate cancer	0.00433	0.00913	CbGbCtD
Irbesartan—CYP2D6—Doxorubicin—prostate cancer	0.00353	0.00743	CbGbCtD
Irbesartan—CYP3A4—Etoposide—prostate cancer	0.00329	0.00693	CbGbCtD
Irbesartan—CYP3A4—Docetaxel—prostate cancer	0.00301	0.00634	CbGbCtD
Irbesartan—Losartan—UGT2B17—prostate cancer	0.00261	0.712	CrCbGaD
Irbesartan—EDNRA—prostate gland—prostate cancer	0.00251	0.0632	CbGeAlD
Irbesartan—CYP1A2—urine—prostate cancer	0.00244	0.0614	CbGeAlD
Irbesartan—CYP2C9—urine—prostate cancer	0.00231	0.0583	CbGeAlD
Irbesartan—JUN—prostate gland—prostate cancer	0.00229	0.0577	CbGeAlD
Irbesartan—CYP3A4—Doxorubicin—prostate cancer	0.00224	0.00473	CbGbCtD
Irbesartan—EDNRA—seminal vesicle—prostate cancer	0.00212	0.0535	CbGeAlD
Irbesartan—JUN—seminal vesicle—prostate cancer	0.00194	0.0488	CbGeAlD
Irbesartan—CYP3A4—urine—prostate cancer	0.00176	0.0444	CbGeAlD
Irbesartan—CYP2D6—urine—prostate cancer	0.00173	0.0437	CbGeAlD
Irbesartan—AGTR1—prostate gland—prostate cancer	0.00172	0.0434	CbGeAlD
Irbesartan—JUN—epithelium—prostate cancer	0.00168	0.0424	CbGeAlD
Irbesartan—EDNRA—urethra—prostate cancer	0.00168	0.0423	CbGeAlD
Irbesartan—JUN—renal system—prostate cancer	0.00156	0.0393	CbGeAlD
Irbesartan—JUN—urethra—prostate cancer	0.00153	0.0386	CbGeAlD
Irbesartan—AGTR1—epithelium—prostate cancer	0.00127	0.0319	CbGeAlD
Irbesartan—JUN—bone marrow—prostate cancer	0.00118	0.0297	CbGeAlD
Irbesartan—AGTR1—renal system—prostate cancer	0.00117	0.0296	CbGeAlD
Irbesartan—EDNRA—testis—prostate cancer	0.0011	0.0279	CbGeAlD
Irbesartan—JUN—testis—prostate cancer	0.00101	0.0254	CbGeAlD
Irbesartan—EDNRA—lymph node—prostate cancer	0.000801	0.0202	CbGeAlD
Irbesartan—AGTR1—testis—prostate cancer	0.000759	0.0191	CbGeAlD
Irbesartan—PTGS1—prostate gland—prostate cancer	0.000758	0.0191	CbGeAlD
Irbesartan—JUN—lymph node—prostate cancer	0.000731	0.0184	CbGeAlD
Irbesartan—PTGS1—seminal vesicle—prostate cancer	0.000641	0.0162	CbGeAlD
Irbesartan—CYP2C8—renal system—prostate cancer	0.000637	0.0161	CbGeAlD
Irbesartan—JUN—Dexamethasone—Prednisone—prostate cancer	0.000619	0.5	CbGdCrCtD
Irbesartan—JUN—Betamethasone—Prednisone—prostate cancer	0.000619	0.5	CbGdCrCtD
Irbesartan—CYP1A2—renal system—prostate cancer	0.000596	0.015	CbGeAlD
Irbesartan—PTGS1—epithelium—prostate cancer	0.000557	0.014	CbGeAlD
Irbesartan—AGTR1—lymph node—prostate cancer	0.00055	0.0139	CbGeAlD
Irbesartan—PTGS1—renal system—prostate cancer	0.000516	0.013	CbGeAlD
Irbesartan—CYP3A4—renal system—prostate cancer	0.000431	0.0109	CbGeAlD
Irbesartan—CYP2D6—renal system—prostate cancer	0.000424	0.0107	CbGeAlD
Irbesartan—CYP2C8—testis—prostate cancer	0.000412	0.0104	CbGeAlD
Irbesartan—PTGS1—testis—prostate cancer	0.000334	0.00841	CbGeAlD
Irbesartan—CYP2D6—testis—prostate cancer	0.000274	0.00692	CbGeAlD
Irbesartan—Tasosartan—CYP3A4—prostate cancer	0.000266	0.0726	CrCbGaD
Irbesartan—Losartan—CYP3A5—prostate cancer	0.00026	0.071	CrCbGaD
Irbesartan—PTGS1—lymph node—prostate cancer	0.000242	0.0061	CbGeAlD
Irbesartan—Losartan—ACE—prostate cancer	0.00024	0.0655	CrCbGaD
Irbesartan—Losartan—CYP2C19—prostate cancer	0.000177	0.0483	CrCbGaD
Irbesartan—Losartan—CYP3A4—prostate cancer	0.000113	0.0307	CrCbGaD
Irbesartan—Vomiting—Mitoxantrone—prostate cancer	3.88e-05	0.000196	CcSEcCtD
Irbesartan—Visual impairment—Epirubicin—prostate cancer	3.86e-05	0.000195	CcSEcCtD
Irbesartan—Agranulocytosis—Doxorubicin—prostate cancer	3.86e-05	0.000195	CcSEcCtD
Irbesartan—Hypertension—Prednisone—prostate cancer	3.85e-05	0.000195	CcSEcCtD
Irbesartan—Rash—Mitoxantrone—prostate cancer	3.85e-05	0.000195	CcSEcCtD
Irbesartan—Dermatitis—Mitoxantrone—prostate cancer	3.85e-05	0.000194	CcSEcCtD
Irbesartan—Musculoskeletal discomfort—Docetaxel—prostate cancer	3.85e-05	0.000194	CcSEcCtD
Irbesartan—Headache—Mitoxantrone—prostate cancer	3.83e-05	0.000193	CcSEcCtD
Irbesartan—Hypotension—Capecitabine—prostate cancer	3.82e-05	0.000193	CcSEcCtD
Irbesartan—Myalgia—Prednisone—prostate cancer	3.8e-05	0.000192	CcSEcCtD
Irbesartan—Arthralgia—Prednisone—prostate cancer	3.8e-05	0.000192	CcSEcCtD
Irbesartan—Paraesthesia—Docetaxel—prostate cancer	3.79e-05	0.000192	CcSEcCtD
Irbesartan—Anxiety—Prednisone—prostate cancer	3.79e-05	0.000191	CcSEcCtD
Irbesartan—Bradycardia—Doxorubicin—prostate cancer	3.78e-05	0.000191	CcSEcCtD
Irbesartan—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	3.77e-05	0.000191	CcSEcCtD
Irbesartan—Dyspnoea—Docetaxel—prostate cancer	3.77e-05	0.00019	CcSEcCtD
Irbesartan—Somnolence—Docetaxel—prostate cancer	3.75e-05	0.00019	CcSEcCtD
Irbesartan—Discomfort—Prednisone—prostate cancer	3.75e-05	0.00019	CcSEcCtD
Irbesartan—Hypersensitivity—Etoposide—prostate cancer	3.74e-05	0.000189	CcSEcCtD
Irbesartan—Tinnitus—Epirubicin—prostate cancer	3.74e-05	0.000189	CcSEcCtD
Irbesartan—Musculoskeletal discomfort—Capecitabine—prostate cancer	3.73e-05	0.000188	CcSEcCtD
Irbesartan—Cardiac disorder—Epirubicin—prostate cancer	3.72e-05	0.000188	CcSEcCtD
Irbesartan—Flushing—Epirubicin—prostate cancer	3.72e-05	0.000188	CcSEcCtD
Irbesartan—Rhinitis—Doxorubicin—prostate cancer	3.72e-05	0.000188	CcSEcCtD
Irbesartan—Dyspepsia—Docetaxel—prostate cancer	3.72e-05	0.000188	CcSEcCtD
Irbesartan—Hepatitis—Doxorubicin—prostate cancer	3.71e-05	0.000187	CcSEcCtD
Irbesartan—Hypoaesthesia—Doxorubicin—prostate cancer	3.69e-05	0.000186	CcSEcCtD
Irbesartan—Pharyngitis—Doxorubicin—prostate cancer	3.68e-05	0.000186	CcSEcCtD
Irbesartan—Paraesthesia—Capecitabine—prostate cancer	3.67e-05	0.000185	CcSEcCtD
Irbesartan—Decreased appetite—Docetaxel—prostate cancer	3.67e-05	0.000185	CcSEcCtD
Irbesartan—Urinary tract disorder—Doxorubicin—prostate cancer	3.66e-05	0.000185	CcSEcCtD
Irbesartan—Oedema peripheral—Doxorubicin—prostate cancer	3.65e-05	0.000185	CcSEcCtD
Irbesartan—Gastrointestinal disorder—Docetaxel—prostate cancer	3.65e-05	0.000184	CcSEcCtD
Irbesartan—Asthenia—Etoposide—prostate cancer	3.65e-05	0.000184	CcSEcCtD
Irbesartan—Connective tissue disorder—Doxorubicin—prostate cancer	3.65e-05	0.000184	CcSEcCtD
Irbesartan—Dyspnoea—Capecitabine—prostate cancer	3.65e-05	0.000184	CcSEcCtD
Irbesartan—Oedema—Prednisone—prostate cancer	3.64e-05	0.000184	CcSEcCtD
Irbesartan—Anaphylactic shock—Prednisone—prostate cancer	3.64e-05	0.000184	CcSEcCtD
Irbesartan—Fatigue—Docetaxel—prostate cancer	3.64e-05	0.000184	CcSEcCtD
Irbesartan—Angiopathy—Epirubicin—prostate cancer	3.64e-05	0.000184	CcSEcCtD
Irbesartan—Urethral disorder—Doxorubicin—prostate cancer	3.64e-05	0.000184	CcSEcCtD
Irbesartan—Nausea—Mitoxantrone—prostate cancer	3.63e-05	0.000183	CcSEcCtD
Irbesartan—Immune system disorder—Epirubicin—prostate cancer	3.62e-05	0.000183	CcSEcCtD
Irbesartan—Infection—Prednisone—prostate cancer	3.62e-05	0.000183	CcSEcCtD
Irbesartan—Mediastinal disorder—Epirubicin—prostate cancer	3.61e-05	0.000183	CcSEcCtD
Irbesartan—Constipation—Docetaxel—prostate cancer	3.61e-05	0.000182	CcSEcCtD
Irbesartan—Pain—Docetaxel—prostate cancer	3.61e-05	0.000182	CcSEcCtD
Irbesartan—Dyspepsia—Capecitabine—prostate cancer	3.6e-05	0.000182	CcSEcCtD
Irbesartan—Chills—Epirubicin—prostate cancer	3.6e-05	0.000182	CcSEcCtD
Irbesartan—Pruritus—Etoposide—prostate cancer	3.6e-05	0.000182	CcSEcCtD
Irbesartan—Shock—Prednisone—prostate cancer	3.58e-05	0.000181	CcSEcCtD
Irbesartan—Arrhythmia—Epirubicin—prostate cancer	3.58e-05	0.000181	CcSEcCtD
Irbesartan—Visual impairment—Doxorubicin—prostate cancer	3.58e-05	0.000181	CcSEcCtD
Irbesartan—Nervous system disorder—Prednisone—prostate cancer	3.57e-05	0.00018	CcSEcCtD
Irbesartan—Tachycardia—Prednisone—prostate cancer	3.55e-05	0.00018	CcSEcCtD
Irbesartan—Decreased appetite—Capecitabine—prostate cancer	3.55e-05	0.00018	CcSEcCtD
Irbesartan—Skin disorder—Prednisone—prostate cancer	3.54e-05	0.000179	CcSEcCtD
Irbesartan—Gastrointestinal disorder—Capecitabine—prostate cancer	3.53e-05	0.000178	CcSEcCtD
Irbesartan—Fatigue—Capecitabine—prostate cancer	3.53e-05	0.000178	CcSEcCtD
Irbesartan—Hyperhidrosis—Prednisone—prostate cancer	3.52e-05	0.000178	CcSEcCtD
Irbesartan—Constipation—Capecitabine—prostate cancer	3.5e-05	0.000177	CcSEcCtD
Irbesartan—Pain—Capecitabine—prostate cancer	3.5e-05	0.000177	CcSEcCtD
Irbesartan—Malnutrition—Epirubicin—prostate cancer	3.49e-05	0.000176	CcSEcCtD
Irbesartan—Erythema—Epirubicin—prostate cancer	3.49e-05	0.000176	CcSEcCtD
Irbesartan—Feeling abnormal—Docetaxel—prostate cancer	3.48e-05	0.000176	CcSEcCtD
Irbesartan—Diarrhoea—Etoposide—prostate cancer	3.48e-05	0.000176	CcSEcCtD
Irbesartan—Anorexia—Prednisone—prostate cancer	3.47e-05	0.000175	CcSEcCtD
Irbesartan—Tinnitus—Doxorubicin—prostate cancer	3.46e-05	0.000175	CcSEcCtD
Irbesartan—Gastrointestinal pain—Docetaxel—prostate cancer	3.45e-05	0.000174	CcSEcCtD
Irbesartan—Cardiac disorder—Doxorubicin—prostate cancer	3.44e-05	0.000174	CcSEcCtD
Irbesartan—Flushing—Doxorubicin—prostate cancer	3.44e-05	0.000174	CcSEcCtD
Irbesartan—Flatulence—Epirubicin—prostate cancer	3.44e-05	0.000174	CcSEcCtD
Irbesartan—Tension—Epirubicin—prostate cancer	3.43e-05	0.000173	CcSEcCtD
Irbesartan—Dysgeusia—Epirubicin—prostate cancer	3.42e-05	0.000173	CcSEcCtD
Irbesartan—Nervousness—Epirubicin—prostate cancer	3.39e-05	0.000171	CcSEcCtD
Irbesartan—Feeling abnormal—Capecitabine—prostate cancer	3.37e-05	0.00017	CcSEcCtD
Irbesartan—Angiopathy—Doxorubicin—prostate cancer	3.37e-05	0.00017	CcSEcCtD
Irbesartan—Dizziness—Etoposide—prostate cancer	3.36e-05	0.00017	CcSEcCtD
Irbesartan—Muscle spasms—Epirubicin—prostate cancer	3.36e-05	0.00017	CcSEcCtD
Irbesartan—Immune system disorder—Doxorubicin—prostate cancer	3.35e-05	0.000169	CcSEcCtD
Irbesartan—Gastrointestinal pain—Capecitabine—prostate cancer	3.34e-05	0.000169	CcSEcCtD
Irbesartan—Mediastinal disorder—Doxorubicin—prostate cancer	3.34e-05	0.000169	CcSEcCtD
Irbesartan—Abdominal pain—Docetaxel—prostate cancer	3.34e-05	0.000169	CcSEcCtD
Irbesartan—Body temperature increased—Docetaxel—prostate cancer	3.34e-05	0.000169	CcSEcCtD
Irbesartan—Chills—Doxorubicin—prostate cancer	3.33e-05	0.000168	CcSEcCtD
Irbesartan—Musculoskeletal discomfort—Prednisone—prostate cancer	3.32e-05	0.000168	CcSEcCtD
Irbesartan—Arrhythmia—Doxorubicin—prostate cancer	3.31e-05	0.000167	CcSEcCtD
Irbesartan—Vision blurred—Epirubicin—prostate cancer	3.29e-05	0.000166	CcSEcCtD
Irbesartan—Paraesthesia—Prednisone—prostate cancer	3.27e-05	0.000165	CcSEcCtD
Irbesartan—Urticaria—Capecitabine—prostate cancer	3.25e-05	0.000164	CcSEcCtD
Irbesartan—Ill-defined disorder—Epirubicin—prostate cancer	3.24e-05	0.000164	CcSEcCtD
Irbesartan—Body temperature increased—Capecitabine—prostate cancer	3.23e-05	0.000163	CcSEcCtD
Irbesartan—Abdominal pain—Capecitabine—prostate cancer	3.23e-05	0.000163	CcSEcCtD
Irbesartan—Vomiting—Etoposide—prostate cancer	3.23e-05	0.000163	CcSEcCtD
Irbesartan—Erythema—Doxorubicin—prostate cancer	3.23e-05	0.000163	CcSEcCtD
Irbesartan—Malnutrition—Doxorubicin—prostate cancer	3.23e-05	0.000163	CcSEcCtD
Irbesartan—Anaemia—Epirubicin—prostate cancer	3.23e-05	0.000163	CcSEcCtD
Irbesartan—Agitation—Epirubicin—prostate cancer	3.21e-05	0.000162	CcSEcCtD
Irbesartan—Dyspepsia—Prednisone—prostate cancer	3.21e-05	0.000162	CcSEcCtD
Irbesartan—Rash—Etoposide—prostate cancer	3.2e-05	0.000162	CcSEcCtD
Irbesartan—Dermatitis—Etoposide—prostate cancer	3.2e-05	0.000162	CcSEcCtD
Irbesartan—Headache—Etoposide—prostate cancer	3.18e-05	0.000161	CcSEcCtD
Irbesartan—Flatulence—Doxorubicin—prostate cancer	3.18e-05	0.000161	CcSEcCtD
Irbesartan—Tension—Doxorubicin—prostate cancer	3.17e-05	0.00016	CcSEcCtD
Irbesartan—Decreased appetite—Prednisone—prostate cancer	3.17e-05	0.00016	CcSEcCtD
Irbesartan—Dysgeusia—Doxorubicin—prostate cancer	3.16e-05	0.00016	CcSEcCtD
Irbesartan—Malaise—Epirubicin—prostate cancer	3.15e-05	0.000159	CcSEcCtD
Irbesartan—Fatigue—Prednisone—prostate cancer	3.14e-05	0.000159	CcSEcCtD
Irbesartan—Nervousness—Doxorubicin—prostate cancer	3.14e-05	0.000158	CcSEcCtD
Irbesartan—Vertigo—Epirubicin—prostate cancer	3.14e-05	0.000158	CcSEcCtD
Irbesartan—Syncope—Epirubicin—prostate cancer	3.13e-05	0.000158	CcSEcCtD
Irbesartan—Leukopenia—Epirubicin—prostate cancer	3.12e-05	0.000158	CcSEcCtD
Irbesartan—Constipation—Prednisone—prostate cancer	3.11e-05	0.000157	CcSEcCtD
Irbesartan—Hypersensitivity—Docetaxel—prostate cancer	3.11e-05	0.000157	CcSEcCtD
Irbesartan—Muscle spasms—Doxorubicin—prostate cancer	3.11e-05	0.000157	CcSEcCtD
Irbesartan—Loss of consciousness—Epirubicin—prostate cancer	3.07e-05	0.000155	CcSEcCtD
Irbesartan—Cough—Epirubicin—prostate cancer	3.05e-05	0.000154	CcSEcCtD
Irbesartan—Vision blurred—Doxorubicin—prostate cancer	3.04e-05	0.000154	CcSEcCtD
Irbesartan—Asthenia—Docetaxel—prostate cancer	3.03e-05	0.000153	CcSEcCtD
Irbesartan—Nausea—Etoposide—prostate cancer	3.02e-05	0.000152	CcSEcCtD
Irbesartan—Hypertension—Epirubicin—prostate cancer	3.01e-05	0.000152	CcSEcCtD
Irbesartan—Hypersensitivity—Capecitabine—prostate cancer	3.01e-05	0.000152	CcSEcCtD
Irbesartan—Feeling abnormal—Prednisone—prostate cancer	3e-05	0.000152	CcSEcCtD
Irbesartan—Ill-defined disorder—Doxorubicin—prostate cancer	3e-05	0.000151	CcSEcCtD
Irbesartan—Pruritus—Docetaxel—prostate cancer	2.99e-05	0.000151	CcSEcCtD
Irbesartan—Anaemia—Doxorubicin—prostate cancer	2.99e-05	0.000151	CcSEcCtD
Irbesartan—Gastrointestinal pain—Prednisone—prostate cancer	2.98e-05	0.00015	CcSEcCtD
Irbesartan—Chest pain—Epirubicin—prostate cancer	2.97e-05	0.00015	CcSEcCtD
Irbesartan—Arthralgia—Epirubicin—prostate cancer	2.97e-05	0.00015	CcSEcCtD
Irbesartan—Myalgia—Epirubicin—prostate cancer	2.97e-05	0.00015	CcSEcCtD
Irbesartan—Agitation—Doxorubicin—prostate cancer	2.97e-05	0.00015	CcSEcCtD
Irbesartan—Anxiety—Epirubicin—prostate cancer	2.96e-05	0.00015	CcSEcCtD
Irbesartan—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	2.95e-05	0.000149	CcSEcCtD
Irbesartan—Discomfort—Epirubicin—prostate cancer	2.94e-05	0.000148	CcSEcCtD
Irbesartan—Asthenia—Capecitabine—prostate cancer	2.93e-05	0.000148	CcSEcCtD
Irbesartan—Malaise—Doxorubicin—prostate cancer	2.91e-05	0.000147	CcSEcCtD
Irbesartan—Dry mouth—Epirubicin—prostate cancer	2.91e-05	0.000147	CcSEcCtD
Irbesartan—Vertigo—Doxorubicin—prostate cancer	2.9e-05	0.000147	CcSEcCtD
Irbesartan—Syncope—Doxorubicin—prostate cancer	2.9e-05	0.000146	CcSEcCtD
Irbesartan—Urticaria—Prednisone—prostate cancer	2.89e-05	0.000146	CcSEcCtD
Irbesartan—Pruritus—Capecitabine—prostate cancer	2.89e-05	0.000146	CcSEcCtD
Irbesartan—Leukopenia—Doxorubicin—prostate cancer	2.89e-05	0.000146	CcSEcCtD
Irbesartan—Diarrhoea—Docetaxel—prostate cancer	2.89e-05	0.000146	CcSEcCtD
Irbesartan—Body temperature increased—Prednisone—prostate cancer	2.88e-05	0.000145	CcSEcCtD
Irbesartan—Abdominal pain—Prednisone—prostate cancer	2.88e-05	0.000145	CcSEcCtD
Irbesartan—Oedema—Epirubicin—prostate cancer	2.85e-05	0.000144	CcSEcCtD
Irbesartan—Anaphylactic shock—Epirubicin—prostate cancer	2.85e-05	0.000144	CcSEcCtD
Irbesartan—Loss of consciousness—Doxorubicin—prostate cancer	2.84e-05	0.000143	CcSEcCtD
Irbesartan—Infection—Epirubicin—prostate cancer	2.83e-05	0.000143	CcSEcCtD
Irbesartan—Cough—Doxorubicin—prostate cancer	2.82e-05	0.000142	CcSEcCtD
Irbesartan—Shock—Epirubicin—prostate cancer	2.8e-05	0.000142	CcSEcCtD
Irbesartan—Diarrhoea—Capecitabine—prostate cancer	2.8e-05	0.000141	CcSEcCtD
Irbesartan—Nervous system disorder—Epirubicin—prostate cancer	2.79e-05	0.000141	CcSEcCtD
Irbesartan—Dizziness—Docetaxel—prostate cancer	2.79e-05	0.000141	CcSEcCtD
Irbesartan—Thrombocytopenia—Epirubicin—prostate cancer	2.79e-05	0.000141	CcSEcCtD
Irbesartan—Hypertension—Doxorubicin—prostate cancer	2.79e-05	0.000141	CcSEcCtD
Irbesartan—Tachycardia—Epirubicin—prostate cancer	2.78e-05	0.00014	CcSEcCtD
Irbesartan—Skin disorder—Epirubicin—prostate cancer	2.77e-05	0.00014	CcSEcCtD
Irbesartan—Hyperhidrosis—Epirubicin—prostate cancer	2.75e-05	0.000139	CcSEcCtD
Irbesartan—Myalgia—Doxorubicin—prostate cancer	2.75e-05	0.000139	CcSEcCtD
Irbesartan—Chest pain—Doxorubicin—prostate cancer	2.75e-05	0.000139	CcSEcCtD
Irbesartan—Arthralgia—Doxorubicin—prostate cancer	2.75e-05	0.000139	CcSEcCtD
Irbesartan—Anxiety—Doxorubicin—prostate cancer	2.74e-05	0.000138	CcSEcCtD
Irbesartan—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	2.73e-05	0.000138	CcSEcCtD
Irbesartan—Discomfort—Doxorubicin—prostate cancer	2.72e-05	0.000137	CcSEcCtD
Irbesartan—Anorexia—Epirubicin—prostate cancer	2.72e-05	0.000137	CcSEcCtD
Irbesartan—Dizziness—Capecitabine—prostate cancer	2.7e-05	0.000137	CcSEcCtD
Irbesartan—Dry mouth—Doxorubicin—prostate cancer	2.69e-05	0.000136	CcSEcCtD
Irbesartan—Vomiting—Docetaxel—prostate cancer	2.69e-05	0.000136	CcSEcCtD
Irbesartan—Hypersensitivity—Prednisone—prostate cancer	2.68e-05	0.000136	CcSEcCtD
Irbesartan—Rash—Docetaxel—prostate cancer	2.66e-05	0.000135	CcSEcCtD
Irbesartan—Hypotension—Epirubicin—prostate cancer	2.66e-05	0.000134	CcSEcCtD
Irbesartan—Dermatitis—Docetaxel—prostate cancer	2.66e-05	0.000134	CcSEcCtD
Irbesartan—Headache—Docetaxel—prostate cancer	2.65e-05	0.000134	CcSEcCtD
Irbesartan—Anaphylactic shock—Doxorubicin—prostate cancer	2.64e-05	0.000133	CcSEcCtD
Irbesartan—Oedema—Doxorubicin—prostate cancer	2.64e-05	0.000133	CcSEcCtD
Irbesartan—Infection—Doxorubicin—prostate cancer	2.62e-05	0.000132	CcSEcCtD
Irbesartan—Asthenia—Prednisone—prostate cancer	2.61e-05	0.000132	CcSEcCtD
Irbesartan—Vomiting—Capecitabine—prostate cancer	2.6e-05	0.000131	CcSEcCtD
Irbesartan—Musculoskeletal discomfort—Epirubicin—prostate cancer	2.6e-05	0.000131	CcSEcCtD
Irbesartan—Shock—Doxorubicin—prostate cancer	2.59e-05	0.000131	CcSEcCtD
Irbesartan—Nervous system disorder—Doxorubicin—prostate cancer	2.58e-05	0.000131	CcSEcCtD
Irbesartan—Thrombocytopenia—Doxorubicin—prostate cancer	2.58e-05	0.00013	CcSEcCtD
Irbesartan—Rash—Capecitabine—prostate cancer	2.58e-05	0.00013	CcSEcCtD
Irbesartan—Pruritus—Prednisone—prostate cancer	2.58e-05	0.00013	CcSEcCtD
Irbesartan—Dermatitis—Capecitabine—prostate cancer	2.58e-05	0.00013	CcSEcCtD
Irbesartan—Tachycardia—Doxorubicin—prostate cancer	2.57e-05	0.00013	CcSEcCtD
Irbesartan—Headache—Capecitabine—prostate cancer	2.56e-05	0.000129	CcSEcCtD
Irbesartan—Skin disorder—Doxorubicin—prostate cancer	2.56e-05	0.000129	CcSEcCtD
Irbesartan—Paraesthesia—Epirubicin—prostate cancer	2.56e-05	0.000129	CcSEcCtD
Irbesartan—Hyperhidrosis—Doxorubicin—prostate cancer	2.55e-05	0.000129	CcSEcCtD
Irbesartan—Dyspnoea—Epirubicin—prostate cancer	2.54e-05	0.000128	CcSEcCtD
Irbesartan—Somnolence—Epirubicin—prostate cancer	2.53e-05	0.000128	CcSEcCtD
Irbesartan—Anorexia—Doxorubicin—prostate cancer	2.51e-05	0.000127	CcSEcCtD
Irbesartan—Nausea—Docetaxel—prostate cancer	2.51e-05	0.000127	CcSEcCtD
Irbesartan—Dyspepsia—Epirubicin—prostate cancer	2.51e-05	0.000127	CcSEcCtD
Irbesartan—Diarrhoea—Prednisone—prostate cancer	2.49e-05	0.000126	CcSEcCtD
Irbesartan—Decreased appetite—Epirubicin—prostate cancer	2.48e-05	0.000125	CcSEcCtD
Irbesartan—Hypotension—Doxorubicin—prostate cancer	2.46e-05	0.000124	CcSEcCtD
Irbesartan—Gastrointestinal disorder—Epirubicin—prostate cancer	2.46e-05	0.000124	CcSEcCtD
Irbesartan—Fatigue—Epirubicin—prostate cancer	2.46e-05	0.000124	CcSEcCtD
Irbesartan—Pain—Epirubicin—prostate cancer	2.44e-05	0.000123	CcSEcCtD
Irbesartan—Constipation—Epirubicin—prostate cancer	2.44e-05	0.000123	CcSEcCtD
Irbesartan—Nausea—Capecitabine—prostate cancer	2.43e-05	0.000123	CcSEcCtD
Irbesartan—Dizziness—Prednisone—prostate cancer	2.41e-05	0.000122	CcSEcCtD
Irbesartan—Musculoskeletal discomfort—Doxorubicin—prostate cancer	2.4e-05	0.000121	CcSEcCtD
Irbesartan—Paraesthesia—Doxorubicin—prostate cancer	2.37e-05	0.00012	CcSEcCtD
Irbesartan—Dyspnoea—Doxorubicin—prostate cancer	2.35e-05	0.000119	CcSEcCtD
Irbesartan—Feeling abnormal—Epirubicin—prostate cancer	2.35e-05	0.000119	CcSEcCtD
Irbesartan—Somnolence—Doxorubicin—prostate cancer	2.34e-05	0.000118	CcSEcCtD
Irbesartan—Gastrointestinal pain—Epirubicin—prostate cancer	2.33e-05	0.000118	CcSEcCtD
Irbesartan—Dyspepsia—Doxorubicin—prostate cancer	2.32e-05	0.000117	CcSEcCtD
Irbesartan—Vomiting—Prednisone—prostate cancer	2.32e-05	0.000117	CcSEcCtD
Irbesartan—Rash—Prednisone—prostate cancer	2.3e-05	0.000116	CcSEcCtD
Irbesartan—Dermatitis—Prednisone—prostate cancer	2.29e-05	0.000116	CcSEcCtD
Irbesartan—Decreased appetite—Doxorubicin—prostate cancer	2.29e-05	0.000116	CcSEcCtD
Irbesartan—Headache—Prednisone—prostate cancer	2.28e-05	0.000115	CcSEcCtD
Irbesartan—Gastrointestinal disorder—Doxorubicin—prostate cancer	2.28e-05	0.000115	CcSEcCtD
Irbesartan—Fatigue—Doxorubicin—prostate cancer	2.27e-05	0.000115	CcSEcCtD
Irbesartan—Urticaria—Epirubicin—prostate cancer	2.26e-05	0.000114	CcSEcCtD
Irbesartan—Constipation—Doxorubicin—prostate cancer	2.25e-05	0.000114	CcSEcCtD
Irbesartan—Pain—Doxorubicin—prostate cancer	2.25e-05	0.000114	CcSEcCtD
Irbesartan—Abdominal pain—Epirubicin—prostate cancer	2.25e-05	0.000114	CcSEcCtD
Irbesartan—Body temperature increased—Epirubicin—prostate cancer	2.25e-05	0.000114	CcSEcCtD
Irbesartan—Feeling abnormal—Doxorubicin—prostate cancer	2.17e-05	0.00011	CcSEcCtD
Irbesartan—Nausea—Prednisone—prostate cancer	2.16e-05	0.000109	CcSEcCtD
Irbesartan—Gastrointestinal pain—Doxorubicin—prostate cancer	2.16e-05	0.000109	CcSEcCtD
Irbesartan—Hypersensitivity—Epirubicin—prostate cancer	2.1e-05	0.000106	CcSEcCtD
Irbesartan—Urticaria—Doxorubicin—prostate cancer	2.09e-05	0.000106	CcSEcCtD
Irbesartan—Body temperature increased—Doxorubicin—prostate cancer	2.08e-05	0.000105	CcSEcCtD
Irbesartan—Abdominal pain—Doxorubicin—prostate cancer	2.08e-05	0.000105	CcSEcCtD
Irbesartan—Asthenia—Epirubicin—prostate cancer	2.04e-05	0.000103	CcSEcCtD
Irbesartan—Pruritus—Epirubicin—prostate cancer	2.02e-05	0.000102	CcSEcCtD
Irbesartan—Diarrhoea—Epirubicin—prostate cancer	1.95e-05	9.85e-05	CcSEcCtD
Irbesartan—Hypersensitivity—Doxorubicin—prostate cancer	1.94e-05	9.81e-05	CcSEcCtD
Irbesartan—Asthenia—Doxorubicin—prostate cancer	1.89e-05	9.55e-05	CcSEcCtD
Irbesartan—Dizziness—Epirubicin—prostate cancer	1.88e-05	9.52e-05	CcSEcCtD
Irbesartan—Pruritus—Doxorubicin—prostate cancer	1.86e-05	9.42e-05	CcSEcCtD
Irbesartan—Vomiting—Epirubicin—prostate cancer	1.81e-05	9.15e-05	CcSEcCtD
Irbesartan—Diarrhoea—Doxorubicin—prostate cancer	1.8e-05	9.11e-05	CcSEcCtD
Irbesartan—Rash—Epirubicin—prostate cancer	1.8e-05	9.07e-05	CcSEcCtD
Irbesartan—Dermatitis—Epirubicin—prostate cancer	1.79e-05	9.06e-05	CcSEcCtD
Irbesartan—Headache—Epirubicin—prostate cancer	1.78e-05	9.01e-05	CcSEcCtD
Irbesartan—Dizziness—Doxorubicin—prostate cancer	1.74e-05	8.8e-05	CcSEcCtD
Irbesartan—Nausea—Epirubicin—prostate cancer	1.69e-05	8.55e-05	CcSEcCtD
Irbesartan—Vomiting—Doxorubicin—prostate cancer	1.68e-05	8.47e-05	CcSEcCtD
Irbesartan—Rash—Doxorubicin—prostate cancer	1.66e-05	8.39e-05	CcSEcCtD
Irbesartan—Dermatitis—Doxorubicin—prostate cancer	1.66e-05	8.39e-05	CcSEcCtD
Irbesartan—Headache—Doxorubicin—prostate cancer	1.65e-05	8.34e-05	CcSEcCtD
Irbesartan—Nausea—Doxorubicin—prostate cancer	1.57e-05	7.91e-05	CcSEcCtD
Irbesartan—CYP3A4—Metabolism—SULT1A1—prostate cancer	2.43e-06	1.44e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—CYP2C19—prostate cancer	2.41e-06	1.43e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—JAK2—prostate cancer	2.4e-06	1.42e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—SLC5A5—prostate cancer	2.39e-06	1.42e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	2.38e-06	1.42e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—VEGFA—prostate cancer	2.38e-06	1.41e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—SLC5A5—prostate cancer	2.37e-06	1.41e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—GSTA1—prostate cancer	2.37e-06	1.41e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—PIK3CA—prostate cancer	2.37e-06	1.41e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—COMT—prostate cancer	2.36e-06	1.4e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—ACHE—prostate cancer	2.36e-06	1.4e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—GSTT1—prostate cancer	2.36e-06	1.4e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—STAT3—prostate cancer	2.35e-06	1.4e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—GSTP1—prostate cancer	2.35e-06	1.39e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—INS—prostate cancer	2.35e-06	1.39e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—HSD3B2—prostate cancer	2.34e-06	1.39e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—GSTO1—prostate cancer	2.34e-06	1.39e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—NAT2—prostate cancer	2.34e-06	1.39e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—MDM2—prostate cancer	2.34e-06	1.39e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—CYP2E1—prostate cancer	2.34e-06	1.39e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—KRAS—prostate cancer	2.34e-06	1.39e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—CYP2A6—prostate cancer	2.33e-06	1.38e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—prostate cancer	2.32e-06	1.38e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—CYP2E1—prostate cancer	2.32e-06	1.38e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—NQO1—prostate cancer	2.31e-06	1.37e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—ITPR1—prostate cancer	2.31e-06	1.37e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—ERBB2—prostate cancer	2.31e-06	1.37e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—CREBBP—prostate cancer	2.3e-06	1.37e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—NQO1—prostate cancer	2.29e-06	1.36e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—TP53—prostate cancer	2.29e-06	1.36e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—TH—prostate cancer	2.28e-06	1.35e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—PIK3CB—prostate cancer	2.28e-06	1.35e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—EP300—prostate cancer	2.27e-06	1.35e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—AKR1C3—prostate cancer	2.26e-06	1.35e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—TH—prostate cancer	2.26e-06	1.34e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—CYP3A4—prostate cancer	2.25e-06	1.34e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—PRKACB—prostate cancer	2.25e-06	1.34e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—CYP2C18—prostate cancer	2.25e-06	1.34e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—LRP2—prostate cancer	2.25e-06	1.34e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—PLCB2—prostate cancer	2.25e-06	1.34e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—prostate cancer	2.24e-06	1.33e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—CYP3A4—prostate cancer	2.23e-06	1.33e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—CYP17A1—prostate cancer	2.23e-06	1.32e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—prostate cancer	2.22e-06	1.32e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—CYP1B1—prostate cancer	2.21e-06	1.32e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—P4HB—prostate cancer	2.2e-06	1.31e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—prostate cancer	2.2e-06	1.31e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—CYP1B1—prostate cancer	2.2e-06	1.3e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—MYC—prostate cancer	2.19e-06	1.3e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—CXCL8—prostate cancer	2.19e-06	1.3e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—TGFB1—prostate cancer	2.18e-06	1.3e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—TYMS—prostate cancer	2.18e-06	1.3e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—PIK3CD—prostate cancer	2.18e-06	1.3e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—GSTM1—prostate cancer	2.16e-06	1.28e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—PIK3CA—prostate cancer	2.15e-06	1.28e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—GGT1—prostate cancer	2.15e-06	1.27e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—SLC22A1—prostate cancer	2.14e-06	1.27e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—EGFR—prostate cancer	2.14e-06	1.27e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—CDKN1B—prostate cancer	2.14e-06	1.27e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—GGT1—prostate cancer	2.13e-06	1.26e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—NCOA2—prostate cancer	2.12e-06	1.26e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—LPL—prostate cancer	2.12e-06	1.26e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—NCOA1—prostate cancer	2.11e-06	1.26e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—IL6—prostate cancer	2.1e-06	1.25e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—NCOA1—prostate cancer	2.09e-06	1.24e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—CASP3—prostate cancer	2.09e-06	1.24e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—IL2—prostate cancer	2.09e-06	1.24e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—SULT2A1—prostate cancer	2.09e-06	1.24e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—CYP19A1—prostate cancer	2.08e-06	1.24e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—CYP19A1—prostate cancer	2.06e-06	1.23e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—NOS3—prostate cancer	2.06e-06	1.22e-05	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—PIK3CA—prostate cancer	2.06e-06	1.22e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—MED12—prostate cancer	2.06e-06	1.22e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—CYP1A1—prostate cancer	2.04e-06	1.22e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—GNG5—prostate cancer	2.04e-06	1.21e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—CCND1—prostate cancer	2.04e-06	1.21e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—ERCC2—prostate cancer	2.03e-06	1.21e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—SLC5A5—prostate cancer	2.03e-06	1.2e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—KRAS—prostate cancer	2.02e-06	1.2e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—CTNNB1—prostate cancer	2.02e-06	1.2e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—RXRA—prostate cancer	2.01e-06	1.19e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—RXRA—prostate cancer	1.99e-06	1.18e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—CYP2E1—prostate cancer	1.98e-06	1.18e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—MMP9—prostate cancer	1.98e-06	1.18e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—CDKN1A—prostate cancer	1.97e-06	1.17e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—PTEN—prostate cancer	1.97e-06	1.17e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—NCOA3—prostate cancer	1.96e-06	1.17e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—NQO1—prostate cancer	1.96e-06	1.16e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	1.94e-06	1.15e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—COMT—prostate cancer	1.94e-06	1.15e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—AKT1—prostate cancer	1.93e-06	1.15e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—TH—prostate cancer	1.93e-06	1.15e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—GSTP1—prostate cancer	1.93e-06	1.15e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—COMT—prostate cancer	1.92e-06	1.14e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—prostate cancer	1.92e-06	1.14e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—GSTP1—prostate cancer	1.91e-06	1.14e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—CYP3A4—prostate cancer	1.91e-06	1.13e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—MTHFR—prostate cancer	1.91e-06	1.13e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—IL6—prostate cancer	1.9e-06	1.13e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—PIK3CB—prostate cancer	1.9e-06	1.13e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—prostate cancer	1.9e-06	1.13e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—ITPR1—prostate cancer	1.9e-06	1.13e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—PTGS2—prostate cancer	1.88e-06	1.12e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—ITPR1—prostate cancer	1.88e-06	1.12e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—CYP1B1—prostate cancer	1.88e-06	1.12e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—EP300—prostate cancer	1.88e-06	1.11e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—HPGDS—prostate cancer	1.87e-06	1.11e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—PPARA—prostate cancer	1.87e-06	1.11e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—CYP2C19—prostate cancer	1.86e-06	1.11e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—PIK3CA—prostate cancer	1.86e-06	1.1e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—EP300—prostate cancer	1.85e-06	1.1e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—SRC—prostate cancer	1.82e-06	1.08e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—GSTT1—prostate cancer	1.82e-06	1.08e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—ACHE—prostate cancer	1.82e-06	1.08e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—GGT1—prostate cancer	1.82e-06	1.08e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—CYP2A6—prostate cancer	1.8e-06	1.07e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—TP53—prostate cancer	1.8e-06	1.07e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—TYMS—prostate cancer	1.79e-06	1.06e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—NCOA1—prostate cancer	1.79e-06	1.06e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—VEGFA—prostate cancer	1.78e-06	1.06e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—TYMS—prostate cancer	1.78e-06	1.06e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—GSTM1—prostate cancer	1.77e-06	1.05e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—CYP19A1—prostate cancer	1.76e-06	1.05e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—STAT3—prostate cancer	1.76e-06	1.05e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—CAV1—prostate cancer	1.76e-06	1.04e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—GSTM1—prostate cancer	1.76e-06	1.04e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—AKT1—prostate cancer	1.75e-06	1.04e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—AKR1C3—prostate cancer	1.75e-06	1.04e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—PRKACB—prostate cancer	1.74e-06	1.03e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—LPL—prostate cancer	1.74e-06	1.03e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—LPL—prostate cancer	1.72e-06	1.02e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—CYP17A1—prostate cancer	1.72e-06	1.02e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—RXRA—prostate cancer	1.7e-06	1.01e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	1.68e-06	9.98e-06	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—AKT1—prostate cancer	1.68e-06	9.98e-06	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—CYP1A1—prostate cancer	1.68e-06	9.98e-06	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—ERCC2—prostate cancer	1.66e-06	9.89e-06	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—CYP1A1—prostate cancer	1.66e-06	9.89e-06	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	1.66e-06	9.84e-06	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—ERCC2—prostate cancer	1.65e-06	9.81e-06	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—IL6—prostate cancer	1.64e-06	9.77e-06	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—PTEN—prostate cancer	1.64e-06	9.76e-06	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—COMT—prostate cancer	1.64e-06	9.75e-06	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—NCOA2—prostate cancer	1.64e-06	9.74e-06	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—MYC—prostate cancer	1.63e-06	9.71e-06	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—GSTP1—prostate cancer	1.63e-06	9.7e-06	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—TGFB1—prostate cancer	1.63e-06	9.69e-06	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—ITPR1—prostate cancer	1.61e-06	9.55e-06	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—PIK3CG—prostate cancer	1.6e-06	9.52e-06	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—EGFR—prostate cancer	1.6e-06	9.5e-06	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—EP300—prostate cancer	1.58e-06	9.39e-06	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—EP300—prostate cancer	1.57e-06	9.3e-06	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—MTHFR—prostate cancer	1.56e-06	9.3e-06	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—SLC5A5—prostate cancer	1.56e-06	9.29e-06	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—MTHFR—prostate cancer	1.55e-06	9.22e-06	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—PPARA—prostate cancer	1.54e-06	9.12e-06	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—CYP2E1—prostate cancer	1.53e-06	9.08e-06	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—PPARA—prostate cancer	1.52e-06	9.05e-06	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—TYMS—prostate cancer	1.52e-06	9.02e-06	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—AKT1—prostate cancer	1.52e-06	9.02e-06	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—INS—prostate cancer	1.52e-06	9.01e-06	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—NQO1—prostate cancer	1.51e-06	8.98e-06	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—KRAS—prostate cancer	1.51e-06	8.97e-06	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—GSTM1—prostate cancer	1.5e-06	8.91e-06	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—TH—prostate cancer	1.49e-06	8.85e-06	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—CREBBP—prostate cancer	1.48e-06	8.82e-06	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—LPL—prostate cancer	1.47e-06	8.75e-06	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—CYP1B1—prostate cancer	1.45e-06	8.61e-06	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—CAV1—prostate cancer	1.44e-06	8.58e-06	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—CAV1—prostate cancer	1.43e-06	8.5e-06	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—CYP1A1—prostate cancer	1.42e-06	8.45e-06	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—ERCC2—prostate cancer	1.41e-06	8.38e-06	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—PIK3CD—prostate cancer	1.41e-06	8.37e-06	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—GGT1—prostate cancer	1.4e-06	8.34e-06	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—PIK3CA—prostate cancer	1.39e-06	8.24e-06	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—NCOA1—prostate cancer	1.38e-06	8.21e-06	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	1.37e-06	8.12e-06	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—CYP19A1—prostate cancer	1.36e-06	8.09e-06	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—TP53—prostate cancer	1.34e-06	7.98e-06	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—NOS3—prostate cancer	1.33e-06	7.9e-06	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—MTHFR—prostate cancer	1.33e-06	7.88e-06	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—PIK3CG—prostate cancer	1.31e-06	7.81e-06	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—RXRA—prostate cancer	1.31e-06	7.81e-06	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—PIK3CG—prostate cancer	1.3e-06	7.75e-06	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—PPARA—prostate cancer	1.3e-06	7.73e-06	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—COMT—prostate cancer	1.27e-06	7.52e-06	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—GSTP1—prostate cancer	1.26e-06	7.49e-06	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—INS—prostate cancer	1.24e-06	7.4e-06	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—ITPR1—prostate cancer	1.24e-06	7.37e-06	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—INS—prostate cancer	1.23e-06	7.33e-06	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—IL6—prostate cancer	1.23e-06	7.3e-06	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—PIK3CB—prostate cancer	1.23e-06	7.29e-06	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—CAV1—prostate cancer	1.22e-06	7.27e-06	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—CREBBP—prostate cancer	1.22e-06	7.24e-06	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—PTGS2—prostate cancer	1.22e-06	7.23e-06	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—CREBBP—prostate cancer	1.21e-06	7.18e-06	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—TYMS—prostate cancer	1.17e-06	6.96e-06	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	1.17e-06	6.94e-06	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—PIK3CA—prostate cancer	1.16e-06	6.88e-06	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—GSTM1—prostate cancer	1.16e-06	6.88e-06	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—PIK3CD—prostate cancer	1.16e-06	6.87e-06	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—PIK3CD—prostate cancer	1.15e-06	6.81e-06	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—LPL—prostate cancer	1.14e-06	6.75e-06	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—AKT1—prostate cancer	1.13e-06	6.74e-06	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—PIK3CG—prostate cancer	1.11e-06	6.62e-06	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—CYP1A1—prostate cancer	1.1e-06	6.52e-06	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—NOS3—prostate cancer	1.09e-06	6.49e-06	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—ERCC2—prostate cancer	1.09e-06	6.47e-06	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—NOS3—prostate cancer	1.08e-06	6.43e-06	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—PTEN—prostate cancer	1.06e-06	6.3e-06	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—INS—prostate cancer	1.05e-06	6.27e-06	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—CREBBP—prostate cancer	1.03e-06	6.14e-06	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—MTHFR—prostate cancer	1.02e-06	6.08e-06	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—EP300—prostate cancer	1.01e-06	6.01e-06	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—PIK3CB—prostate cancer	1.01e-06	5.99e-06	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—PPARA—prostate cancer	1e-06	5.97e-06	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—PIK3CB—prostate cancer	9.99e-07	5.94e-06	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—PTGS2—prostate cancer	9.98e-07	5.93e-06	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—PTGS2—prostate cancer	9.9e-07	5.88e-06	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—PIK3CD—prostate cancer	9.79e-07	5.82e-06	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—AKT1—prostate cancer	9.46e-07	5.62e-06	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—CAV1—prostate cancer	9.44e-07	5.61e-06	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—NOS3—prostate cancer	9.25e-07	5.5e-06	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—PTEN—prostate cancer	8.71e-07	5.17e-06	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—PTEN—prostate cancer	8.63e-07	5.13e-06	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—PIK3CG—prostate cancer	8.6e-07	5.11e-06	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—PIK3CB—prostate cancer	8.53e-07	5.07e-06	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—PTGS2—prostate cancer	8.46e-07	5.03e-06	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—EP300—prostate cancer	8.3e-07	4.93e-06	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—EP300—prostate cancer	8.23e-07	4.89e-06	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—INS—prostate cancer	8.14e-07	4.84e-06	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—CREBBP—prostate cancer	7.97e-07	4.74e-06	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—PIK3CD—prostate cancer	7.56e-07	4.49e-06	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—PIK3CA—prostate cancer	7.48e-07	4.45e-06	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—PTEN—prostate cancer	7.38e-07	4.38e-06	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—NOS3—prostate cancer	7.14e-07	4.24e-06	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—EP300—prostate cancer	7.03e-07	4.18e-06	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—PIK3CB—prostate cancer	6.59e-07	3.91e-06	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—PTGS2—prostate cancer	6.53e-07	3.88e-06	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—PIK3CA—prostate cancer	6.14e-07	3.65e-06	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—AKT1—prostate cancer	6.11e-07	3.63e-06	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—PIK3CA—prostate cancer	6.09e-07	3.62e-06	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—PTEN—prostate cancer	5.69e-07	3.38e-06	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—EP300—prostate cancer	5.43e-07	3.23e-06	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—PIK3CA—prostate cancer	5.2e-07	3.09e-06	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—AKT1—prostate cancer	5.02e-07	2.98e-06	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—AKT1—prostate cancer	4.97e-07	2.96e-06	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—AKT1—prostate cancer	4.25e-07	2.53e-06	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—PIK3CA—prostate cancer	4.02e-07	2.39e-06	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—AKT1—prostate cancer	3.28e-07	1.95e-06	CbGpPWpGaD
